Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Tonix Pharma (TNXP).
The Company has initiated a Phase 2 trial for TNX-1300, aiming to treat acute cocaine intoxication, with the first patient already dosed. This study, known as the CATALYST Study, will primarily assess the reduction of systolic blood pressure in patients with acute cocaine intoxication and will also monitor cocaine levels and its metabolites. Meanwhile, the Company emphasizes that its forward-looking statements regarding product development and market prospects are based on current expectations and are subject to risks and uncertainties that could cause actual outcomes to differ significantly.
Learn more about TNXP stock on TipRanks’ Stock Analysis page.